Back to top
more

Hikma Pharmaceuticals (HKMPF)

(Delayed Data from OTC)

$25.70 USD

25.70
NA

0.00 (0.00%)

Updated Sep 13, 2024 02:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for HKMPF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Hikma Pharmaceuticals Plc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 205 270 426 327 443
Receivables 873 841 876 792 798
Notes Receivable 0 0 0 0 0
Inventories 891 776 695 757 568
Other Current Assets 131 112 97 46 39
Total Current Assets 2,100 1,999 2,094 1,922 1,848
Net Property & Equipment 1,096 1,024 1,072 1,009 912
Investments & Advances 113 75 57 48 43
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 226 192 183 221 243
Intangibles 1,100 1,124 892 876 834
Deposits & Other Assets 0 0 0 0 0
Total Assets 4,680 4,471 4,372 4,135 3,930
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 568 476 468 470 473
Current Portion Long-Term Debt 150 139 112 158 569
Current Portion Capital Leases 11 9 9 10 9
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 74 73 57 72 82
Other Current Liabilities 536 380 370 318 338
Total Current Liabilities 1,339 1,077 1,016 1,028 1,471
Mortgages 0 0 0 0 0
Deferred Taxes/Income 25 19 24 31 20
Convertible Debt 0 0 0 0 0
Long-Term Debt 975 1,074 651 692 48
Non-Current Capital Leases 55 61 74 72 59
Other Non-Current Liabilities 77 92 140 164 203
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,471 2,323 1,905 1,987 1,801
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 40 40 42 41 41
Capital Surplus 282 282 282 282 282
Retained Earnings 2,158 2,092 2,189 1,892 1,973
Other Equity -271 -266 -46 -67 -167
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 2,209 2,148 2,467 2,148 2,129
Total Liabilities & Shareholder's Equity 4,680 4,471 4,372 4,135 3,930
Total Common Equity 2,209 2,148 2,467 2,148 2,129
Shares Outstanding 220.20 220.20 242.30 242.30 242.30
Book Value Per Share 10.03 9.75 10.18 8.87 8.79

Fiscal Year End for Hikma Pharmaceuticals Plc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 205 -99,999 -99,727
Receivables NA NA 873 NA 905
Notes Receivable NA NA 0 NA NA
Inventories NA NA 891 NA 859
Other Current Assets NA NA 131 NA 140
Total Current Assets NA NA 2,100 NA 2,176
Net Property & Equipment NA NA 1,096 NA 1,032
Investments & Advances NA NA 113 NA 72
Other Non-Current Assets NA NA 0 NA NA
Deferred Charges NA NA 226 NA 200
Intangibles NA NA 1,100 NA 1,084
Deposits & Other Assets NA NA 0 NA NA
Total Assets NA NA 4,680 NA 4,619
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA 0 NA NA
Accounts Payable NA NA 568 NA 505
Current Portion Long-Term Debt NA NA 150 NA 211
Current Portion Capital Leases NA NA 11 NA 10
Accrued Expenses NA NA 0 NA NA
Income Taxes Payable NA NA 74 NA 73
Other Current Liabilities NA NA 536 NA 416
Total Current Liabilities NA NA 1,339 NA 1,215
Mortgages NA NA 0 NA NA
Deferred Taxes/Income NA NA 25 NA 26
Convertible Debt NA NA 0 NA NA
Long-Term Debt NA NA 975 NA 1,032
Non-Current Capital Leases NA NA 55 NA 59
Other Non-Current Liabilities NA 77 NA 85
Minority Interest (Liabilities) NA NA 0 NA NA
Total Liabilities NA NA 2,471 NA 2,417
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA 0 NA NA
Common Stock (Par) NA NA 40 NA 40
Capital Surplus NA NA 282 NA 282
Retained Earnings NA NA 2,158 NA 2,146
Other Equity NA NA -271 NA -266
Treasury Stock NA NA 0 NA NA
Total Shareholder's Equity NA NA 2,209 NA 2,202
Total Liabilities & Shareholder's Equity NA NA 4,680 NA 4,619
Total Common Equity 0 0 2,209 0 102,201
Shares Outstanding 220.20 220.20 220.20 220.20 220.20
Book Value Per Share 0.00 0.00 10.03 0.00 464.13